12:36 PM EDT, 03/21/2024 (MT Newswires) -- Novo Nordisk ( NVO ) said Thursday the European Medicines Agency's Committee for Medicinal Products for Human Use recommended marketing authorization for Awiqli to treat diabetes in adults.

The committee's positive opinion was backed by findings from the phase 3a clinical trial program, which showed that Awiqli, or once-weekly basal insulin icodec, proved more effective in reducing blood sugar levels and keeping them within the recommended range compared with daily basal insulin in people with type 2 diabetes, the company said.

Awiqli had a safe and well-tolerated profile across the program, the company said,

The company expects to receive final marketing authorization from the European Commission in two months.

Price: 130.30, Change: -0.06, Percent Change: -0.05